AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
← catalyst calendarNCT06548152 · readout in 134 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Hospitalidee, Hospitalidee has been asserted to be a valid organization name by UHToulouse.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
120estimated
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-28 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia
Primary outcome
what the primary-completion date above is the date OFTo measure QoL score of CLL patients treated with acalabrutinib, from treatment initiation and up to 12 months
measured From treatment initiation and up to 12 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed